Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 1Thoracic 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Rectal Neoplasms 1Neoplasms 1Liver Diseases 1Hepatitis 1Gastrointestinal Neoplasms 1Fibrosis 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 512Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 228Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × bavituximab × Gastrointestinal × Clear all
NCT03519997 2026-02-11

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Active not recruiting
35 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

University of Texas Southwestern Medical Center

Phase 2 Terminated
1 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01264705 2020-11-12

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Completed
47 enrolled 10 charts
Gastrointestinal

Fibrosis, Gastrointestinal Neoplasms, Hepatitis, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT01634685 2020-08-20

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

University of Texas Southwestern Medical Center

Phase 1 Completed
15 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡